03 September 2025
03 September 2025
Despite a trial failure in Parkinson鈥檚 disease, Novartis is having a second bite of the alpha-synuclein cherry with Arrowhead鈥檚 drug.
Construction will commence in the third quarter of 2025.
With Novo Nordisk鈥檚 semaglutide patent set to expire in China in 2026, local companies are readying generics to grasp market share.
The integrated service aims to streamline the journey of mRNA drug products from conception to clinical trials.
The programme seeks to combine Oxford's strengths in vaccine development with EIT's AI tech advancements.
Trump has asked pharma companies to justify efficacy for their Covid-19 drugs as he attempts to quell unrest in his administration.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
